I wouldnt really know what PE ratio you could apply @Glyco I havent seen a speccy ever make $40m revenue.
Speaking to management Matthew, Mark and Patrick all seem confident they can hit $40m, so the PE could be ridiculous. And I guess it would be the first speccy to make that much revenue I guess thats why Mark said "I want to see IAM as the most successful startup Australia has seen in the last decade"
Looking at some techs recently
FBR: 120m+ MC, 0 revenue, 800k+ cash burn/qtr
SAS: 100m MC, 0 revenue, 800k+ cash burn/qtr
Then you have older runners like
BRN: 400m MC, 0 revenue, large cash burn
TV2: Almost 100m MC, $20k revenue, large cash burn
XPE: FY16 reached a MC of $150m+, $43k revenue (However it made 270k revenue last qtr and $2.7m cash burn), $ -3m EBIT
All of these were given ridiculous PE's. No guessing what the market will give IAM. But assuming they take into consideration IAM is a sole monopoly of a industry, impossible barriers to entry, aggressive growth strategy via acquisition, top tier management in due time they should be given a ridiculously high PE.
IAM current: $70m MC, $205k revenue, $1.1m burn (mostly listing costs expected $580k burn/qtr), P.C mentioned they couldve been cashflow neutral if it wasnt for all the startup expenses. Already ahead of all the companies above in our first quarter.
IAM by next two quarters: Cumulative $1m revenue (They expect M1 to be hit by then), Cumulative $1.1m burn, more or lesscashflow neutral.
IAM by next year: $40m revenue, Cashflow positive. Now compare this to the other techs above. As M.F said "how do you put a price" on that. Would have a ridiculous MC if it was given a ridiculous PE like the techs above.
And even if it wasnt given a ridiculous PE in the next two quarters and just a modest one we would still have an MC higher than those above imo (BRN excluded)
- Forums
- ASX - By Stock
- Summary of all investor Seminars - The next chapter
CF1
complii fintech solutions ltd
Add to My Watchlist
0.00%
!
2.4¢

I wouldnt really know what PE ratio you could apply @Glyco I...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.71M |
Open | High | Low | Value | Volume |
2.4¢ | 2.7¢ | 2.4¢ | $13.86K | 573.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 200000 | 2.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.6¢ | 500000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200000 | 0.022 |
1 | 250000 | 0.021 |
2 | 73125 | 0.020 |
3 | 912562 | 0.015 |
1 | 70000 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.026 | 500000 | 1 |
0.028 | 506514 | 2 |
0.029 | 113723 | 1 |
0.030 | 500000 | 1 |
0.039 | 110820 | 1 |
Last trade - 14.44pm 04/07/2025 (20 minute delay) ? |
Featured News
CF1 (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online